

RECEIVED 624
MAY 2 8 2003 5/21/03
Docket No.: 5441-D1
TECH CENTER 1600/2900
S9

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT : DANETTE ANDREA DUDLEY EXAMINER :

SERIAL NO. : 10/038,006✓ ART UNIT : 1624

FILED : January 4, 2002 ✓ PAPER NO :

FOR : QUINOXALINONES AS SERINE PROTEASE INHIBITORS ✓

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT (37 C.F.R. §1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 on: May 14, 2003

May 14, 2003

(Date)

Diane L. Hetzler

(Signature of person mailing)
Diane L. Hetzler
(Typed or printed name of person)

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due.

In accordance with 37 C.F.R. §1.98(a)(2), a copy of each document or other information listed on the enclosed Form 1449 is provided.

A concise explanation of the relevance of each non-English language document or other information is as follows (37 C.F.R. §1.98(a)(3)):

1) JP 63-301874: As can be determined from the English language abstract of JP 63-301874 included on the Form 1449, JP 63-301874 discloses quinoxaline derivatives expressed by formula I and their preparation where R¹ and R² are each H or halogen; R³ is a (lower)alkyl which may have one or more proper substituent groups; R⁴ is (protected)carboxy; A is O or S; and Z is lower alkylene and salts thereof. JP 63-301874 also discloses that such compounds exhibit aldose reductase inhibiting activity and are effective in treating complications associated with diabetes such as corneal wound healing defect, cataract, nervous disease cell membrane disease or renal disease.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicants do not represent that a reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached

Form 1449, marked as being considered and initialed by the Examiner, to the
undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit
Account No. 23-0455.

Dated: May 14, 2003

Respectfully submitted,



Andrew J. Leon
Registration No. 46,869
Warner-Lambert Company
2800 Plymouth Road
Ann Arbor, MI 48105
Telephone: (734) 622-4047
Facsimile: (734) 622-1553



#5

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are req

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of 2

Complete if Known

Application Number	10/038,006
Filing Date	January 4, 2002
First Named Inventor	Dudley, D.A. et al
Art Unit	1624
Examiner Name	
Attorney Docket Number	5711-DI-01

RECEIVED
MAY 20 2003
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
		WO 98/13368 A1	04/02/1998	Astra Aktiebolag		
		JP 63-301874	12/08/1988	Fujisawa Pharma		

Examiner Signature		Date Considered
-----------------------	--	--------------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ A applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449(BTO)

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shu

1

1

13

Application Note

Application Number	10/038,006
Filing Date	January 4, 2002
First Named Inventor	Dudley, D.A. et al
Art Unit	1624
Examiner Name	
Attorney Docket Number	5711-D1-01

NON-PATENT LITERATURE DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). **2** Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.